E
StimCell Energetics Inc.
STME
$0.28
$0.013.70%
E
Sell
12/30/2024Downgrade
StimCell Energetics Inc. (STME) was downgraded to E+ from D- on 12/30/2024 due to a decline in the valuation index.
StimCell Energetics Inc. (STME) was downgraded to E+ from D- on 12/30/2024 due to a decline in the valuation index.
D
Sell
12/13/2024Upgraded
StimCell Energetics Inc. (STME) was upgraded to D- from E+ on 12/13/2024 due to an increase in the total return index and valuation index.
StimCell Energetics Inc. (STME) was upgraded to D- from E+ on 12/13/2024 due to an increase in the total return index and valuation index.
E
Sell
11/4/2024Downgrade
StimCell Energetics Inc. (CMXCD) was downgraded to E+ from D- on 11/4/2024 due to a substantial decline in the valuation index and growth index.
StimCell Energetics Inc. (CMXCD) was downgraded to E+ from D- on 11/4/2024 due to a substantial decline in the valuation index and growth index.
D
Sell
6/30/2023Upgraded
Cell MedX Corp. (CMXC) was upgraded to D- from E+ on 6/30/2023 due to an increase in the volatility index.
Cell MedX Corp. (CMXC) was upgraded to D- from E+ on 6/30/2023 due to an increase in the volatility index.
E
Sell
6/13/2023Downgrade
Cell MedX Corp. (CMXC) was downgraded to E+ from D- on 6/13/2023 due to a decline in the volatility index.
Cell MedX Corp. (CMXC) was downgraded to E+ from D- on 6/13/2023 due to a decline in the volatility index.
D
Sell
5/30/2023Upgraded
Cell MedX Corp. (CMXC) was upgraded to D- from E+ on 5/30/2023 due to a substantial increase in the valuation index and volatility index.
Cell MedX Corp. (CMXC) was upgraded to D- from E+ on 5/30/2023 due to a substantial increase in the valuation index and volatility index.
E
Sell
3/14/2023Downgrade
StimCell Energetics Inc. (STME) was downgraded to E+ from D- on 03/14/2023.
StimCell Energetics Inc. (STME) was downgraded to E+ from D- on 03/14/2023.
D
Sell
2/24/2023Downgrade
Cell MedX Corp. (CMXC) was downgraded to D- from D on 2/24/2023 due to a decline in the volatility index and total return index.
Cell MedX Corp. (CMXC) was downgraded to D- from D on 2/24/2023 due to a decline in the volatility index and total return index.
D
Sell
2/9/2023Upgraded
Cell MedX Corp. (CMXC) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index and total return index.
Cell MedX Corp. (CMXC) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index and total return index.
E
Sell
2/8/2023Downgrade
Cell MedX Corp. (CMXC) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index and total return index.
Cell MedX Corp. (CMXC) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index and total return index.
D
Sell
1/26/2023Upgraded
Cell MedX Corp. (CMXC) was upgraded to D from D- on 1/26/2023 due to an increase in the volatility index.
Cell MedX Corp. (CMXC) was upgraded to D from D- on 1/26/2023 due to an increase in the volatility index.
D
Sell
1/9/2023Downgrade
Cell MedX Corp. (CMXC) was downgraded to D- from D on 1/9/2023 due to a decline in the volatility index and total return index.
Cell MedX Corp. (CMXC) was downgraded to D- from D on 1/9/2023 due to a decline in the volatility index and total return index.
D
Sell
12/23/2022Upgraded
Cell MedX Corp. (CMXC) was upgraded to D from D- on 12/23/2022 due to an increase in the total return index, volatility index and valuation index.
Cell MedX Corp. (CMXC) was upgraded to D from D- on 12/23/2022 due to an increase in the total return index, volatility index and valuation index.
D
Sell
12/8/2022Downgrade
Cell MedX Corp. (CMXC) was downgraded to D- from D on 12/8/2022 due to a decline in the total return index and volatility index.
Cell MedX Corp. (CMXC) was downgraded to D- from D on 12/8/2022 due to a decline in the total return index and volatility index.
D
Sell
10/21/2022Upgraded
Cell MedX Corp. (CMXC) was upgraded to D from D- on 10/21/2022 due to an increase in the total return index and volatility index.
Cell MedX Corp. (CMXC) was upgraded to D from D- on 10/21/2022 due to an increase in the total return index and volatility index.
D
Sell
10/6/2022Downgrade
Cell MedX Corp. (CMXC) was downgraded to D- from D on 10/6/2022 due to a decline in the volatility index and valuation index.
Cell MedX Corp. (CMXC) was downgraded to D- from D on 10/6/2022 due to a decline in the volatility index and valuation index.
D
Sell
9/13/2022Upgraded
Cell MedX Corp. (CMXC) was upgraded to D from D- on 9/13/2022 due to an increase in the volatility index and valuation index.
Cell MedX Corp. (CMXC) was upgraded to D from D- on 9/13/2022 due to an increase in the volatility index and valuation index.
D
Sell
8/29/2022Downgrade
Cell MedX Corp. (CMXC) was downgraded to D- from D on 8/29/2022 due to a decline in the total return index and volatility index.
Cell MedX Corp. (CMXC) was downgraded to D- from D on 8/29/2022 due to a decline in the total return index and volatility index.
D
Sell
5/16/2022Upgraded
Cell MedX Corp. (CMXC) was upgraded to D from E+ on 5/16/2022 due to an increase in the total return index.
Cell MedX Corp. (CMXC) was upgraded to D from E+ on 5/16/2022 due to an increase in the total return index.
E
Sell
5/13/2022Downgrade
Cell MedX Corp. (CMXC) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.
Cell MedX Corp. (CMXC) was downgraded to E+ from D on 5/13/2022 due to a decline in the total return index.
D
Sell
5/4/2022Upgraded
Cell MedX Corp. (CMXC) was upgraded to D from E+ on 5/4/2022 due to an increase in the total return index.
Cell MedX Corp. (CMXC) was upgraded to D from E+ on 5/4/2022 due to an increase in the total return index.
E
Sell
5/1/2022Downgrade
StimCell Energetics Inc. (STME) was downgraded to E+ from D on 05/01/2022.
StimCell Energetics Inc. (STME) was downgraded to E+ from D on 05/01/2022.
D
Sell
4/21/2022Upgraded
StimCell Energetics Inc. (STME) was upgraded to D from E+ on 04/21/2022.
StimCell Energetics Inc. (STME) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
Cell MedX Corp. (CMXC) was downgraded to E+ from D on 4/20/2022 due to a large decline in the total return index, volatility index and growth index. Total revenue declined 76.47% from $1.7 to $400.
Cell MedX Corp. (CMXC) was downgraded to E+ from D on 4/20/2022 due to a large decline in the total return index, volatility index and growth index. Total revenue declined 76.47% from $1.7 to $400.
D
Sell
11/9/2021Upgraded
Cell MedX Corp. (CMXC) was upgraded to D from E+ on 11/9/2021 due to an increase in the valuation index.
Cell MedX Corp. (CMXC) was upgraded to D from E+ on 11/9/2021 due to an increase in the valuation index.
E
Sell
11/8/2021Downgrade
Cell MedX Corp. (CMXC) was downgraded to E+ from D on 11/8/2021 due to a decline in the total return index and volatility index.
Cell MedX Corp. (CMXC) was downgraded to E+ from D on 11/8/2021 due to a decline in the total return index and volatility index.
D
Sell
10/18/2021Upgraded
Cell MedX Corp. (CMXC) was upgraded to D from D- on 10/18/2021 due to a large increase in the growth index and volatility index. Total revenue increased 220% from -$1 to $1.2, and earnings per share increased from -$0.0057 to -$0.0038.
Cell MedX Corp. (CMXC) was upgraded to D from D- on 10/18/2021 due to a large increase in the growth index and volatility index. Total revenue increased 220% from -$1 to $1.2, and earnings per share increased from -$0.0057 to -$0.0038.
D
Sell
9/7/2021Downgrade
Cell MedX Corp. (CMXC) was downgraded to D- from D on 9/7/2021 due to a major decline in the total return index, growth index and solvency index. Earnings per share declined from -$0.003 to -$0.0102, total revenue declined 122.73% from $4.4 to -$1, and operating cash flow declined 49.85% from -$98.7 to -$147.9.
Cell MedX Corp. (CMXC) was downgraded to D- from D on 9/7/2021 due to a major decline in the total return index, growth index and solvency index. Earnings per share declined from -$0.003 to -$0.0102, total revenue declined 122.73% from $4.4 to -$1, and operating cash flow declined 49.85% from -$98.7 to -$147.9.
D
Sell
5/15/2020Downgrade
Cell MedX Corp. (CMXC) was downgraded to D from D+ on 5/15/2020 due to a significant decline in the efficiency index and valuation index.
Cell MedX Corp. (CMXC) was downgraded to D from D+ on 5/15/2020 due to a significant decline in the efficiency index and valuation index.
D
Sell
4/30/2020Upgraded
Cell MedX Corp. (CMXC) was upgraded to D+ from D on 4/30/2020 due to an increase in the growth index and total return index.
Cell MedX Corp. (CMXC) was upgraded to D+ from D on 4/30/2020 due to an increase in the growth index and total return index.
D
Sell
4/15/2020Downgrade
Cell MedX Corp. (CMXC) was downgraded to D from C- on 4/15/2020 due to a significant decline in the total return index, solvency index and volatility index. The quick ratio declined from 0.16 to 0.07.
Cell MedX Corp. (CMXC) was downgraded to D from C- on 4/15/2020 due to a significant decline in the total return index, solvency index and volatility index. The quick ratio declined from 0.16 to 0.07.
C
Hold
10/17/2019Downgrade
Cell MedX Corp. (CMXC) was downgraded to C- from C on 10/17/2019 due to a major decline in the growth index and volatility index. Earnings per share declined from -$0.0033 to -$0.01, operating cash flow declined 99.71% from -$102 to -$203.7, and EBIT declined 73.56% from -$137.3 to -$238.3.
Cell MedX Corp. (CMXC) was downgraded to C- from C on 10/17/2019 due to a major decline in the growth index and volatility index. Earnings per share declined from -$0.0033 to -$0.01, operating cash flow declined 99.71% from -$102 to -$203.7, and EBIT declined 73.56% from -$137.3 to -$238.3.
C
Hold
9/9/2019Upgraded
Cell MedX Corp. (CMXC) was upgraded to C from C- on 9/9/2019 due to a major increase in the total return index, growth index and solvency index. Earnings per share increased from -$0.0088 to -$0.0033, operating cash flow increased 28.22% from -$142.1 to -$102, and EBIT increased 17.83% from -$167.1 to -$137.3.
Cell MedX Corp. (CMXC) was upgraded to C from C- on 9/9/2019 due to a major increase in the total return index, growth index and solvency index. Earnings per share increased from -$0.0088 to -$0.0033, operating cash flow increased 28.22% from -$142.1 to -$102, and EBIT increased 17.83% from -$167.1 to -$137.3.
C
Hold
7/30/2019Upgraded
Cell MedX Corp. (CMXC) was upgraded to C- from D+ on 7/30/2019 due to a noticeable increase in the total return index, volatility index and growth index.
Cell MedX Corp. (CMXC) was upgraded to C- from D+ on 7/30/2019 due to a noticeable increase in the total return index, volatility index and growth index.
D
Sell
4/23/2019Downgrade
Cell MedX Corp. (CMXC) was downgraded to D+ from C- on 4/23/2019 due to a large decline in the growth index. Operating cash flow declined 740.83% from -$16.9 to -$142.1, earnings per share declined from -$0.0029 to -$0.01, and EBIT declined 33.79% from -$124.9 to -$167.1.
Cell MedX Corp. (CMXC) was downgraded to D+ from C- on 4/23/2019 due to a large decline in the growth index. Operating cash flow declined 740.83% from -$16.9 to -$142.1, earnings per share declined from -$0.0029 to -$0.01, and EBIT declined 33.79% from -$124.9 to -$167.1.
C
Hold
2/15/2019Upgraded
Cell MedX Corp. (CMXC) was upgraded to C- from D+ on 2/15/2019 due to a noticeable increase in the volatility index, total return index and growth index. Operating cash flow increased 63.73% from -$46.6 to -$16.9, EBIT increased 48.24% from -$241.3 to -$124.9, and earnings per share increased from -$0.0055 to -$0.0029.
Cell MedX Corp. (CMXC) was upgraded to C- from D+ on 2/15/2019 due to a noticeable increase in the volatility index, total return index and growth index. Operating cash flow increased 63.73% from -$46.6 to -$16.9, EBIT increased 48.24% from -$241.3 to -$124.9, and earnings per share increased from -$0.0055 to -$0.0029.
D
Sell
10/22/2018Upgraded
Cell MedX Corp. (CMXC) was upgraded to D+ from D on 10/22/2018 due to a major increase in the growth index and valuation index. Earnings per share increased from -$0.0058 to -$0.0055.
Cell MedX Corp. (CMXC) was upgraded to D+ from D on 10/22/2018 due to a major increase in the growth index and valuation index. Earnings per share increased from -$0.0058 to -$0.0055.
D
Sell
5/17/2018Downgrade
Cell MedX Corp. (CMXC) was downgraded to D from D+ on 5/17/2018 due to a decline in the volatility index and total return index.
Cell MedX Corp. (CMXC) was downgraded to D from D+ on 5/17/2018 due to a decline in the volatility index and total return index.
D
Sell
5/2/2018Upgraded
Cell MedX Corp. (CMXC) was upgraded to D+ from D on 5/2/2018 due to an increase in the volatility index.
Cell MedX Corp. (CMXC) was upgraded to D+ from D on 5/2/2018 due to an increase in the volatility index.
D
Sell
4/17/2018Downgrade
Cell MedX Corp. (CMXC) was downgraded to D from D+ on 4/17/2018 due to a large decline in the total return index, growth index and volatility index. Earnings per share declined from -$0.0043 to -$0.01, and EBIT declined 62.56% from -$181.1 to -$294.4.
Cell MedX Corp. (CMXC) was downgraded to D from D+ on 4/17/2018 due to a large decline in the total return index, growth index and volatility index. Earnings per share declined from -$0.0043 to -$0.01, and EBIT declined 62.56% from -$181.1 to -$294.4.
D
Sell
1/17/2018Upgraded
Cell MedX Corp. (CMXC) was upgraded to D+ from D on 1/17/2018 due to a noticeable increase in the growth index. Earnings per share increased from -$0.0207 to -$0.0043, and EBIT increased 78.06% from -$825.4 to -$181.1.
Cell MedX Corp. (CMXC) was upgraded to D+ from D on 1/17/2018 due to a noticeable increase in the growth index. Earnings per share increased from -$0.0207 to -$0.0043, and EBIT increased 78.06% from -$825.4 to -$181.1.
D
Sell
10/17/2017Downgrade
Cell MedX Corp. (CMXC) was downgraded to D from C- on 10/17/2017 due to a significant decline in the growth index, efficiency index and valuation index. Net income declined 311.44% from $394.1 to -$833.3, earnings per share declined from $0.0098 to -$0.02, and EBIT declined 92.99% from -$427.7 to -$825.4.
Cell MedX Corp. (CMXC) was downgraded to D from C- on 10/17/2017 due to a significant decline in the growth index, efficiency index and valuation index. Net income declined 311.44% from $394.1 to -$833.3, earnings per share declined from $0.0098 to -$0.02, and EBIT declined 92.99% from -$427.7 to -$825.4.
C
Hold
8/11/2017Downgrade
Cell MedX Corp. (CMXC) was downgraded to C- from C on 8/11/2017 due to a decline in the volatility index.
Cell MedX Corp. (CMXC) was downgraded to C- from C on 8/11/2017 due to a decline in the volatility index.
C
Hold
4/17/2017Upgraded
Cell MedX Corp. (CMXC) was upgraded to C from C- on 4/17/2017 due to a large increase in the total return index, volatility index and efficiency index. Net income increased 71.27% from -$1.06M to -$304.6.
Cell MedX Corp. (CMXC) was upgraded to C from C- on 4/17/2017 due to a large increase in the total return index, volatility index and efficiency index. Net income increased 71.27% from -$1.06M to -$304.6.
C
Hold
10/18/2016Upgraded
Cell MedX Corp. (CMXC) was upgraded to C- from D+ on 10/18/2016 due to a noticeable increase in the growth index, efficiency index and volatility index. Net income increased 16.55% from -$334.1 to -$278.8, EBIT increased 13.17% from -$296.2 to -$257.2, and earnings per share increased from -$0.0108 to -$0.01.
Cell MedX Corp. (CMXC) was upgraded to C- from D+ on 10/18/2016 due to a noticeable increase in the growth index, efficiency index and volatility index. Net income increased 16.55% from -$334.1 to -$278.8, EBIT increased 13.17% from -$296.2 to -$257.2, and earnings per share increased from -$0.0108 to -$0.01.
D
Sell
8/10/2016Downgrade
Cell MedX Corp. (CMXC) was downgraded to D+ from C- on 8/10/2016 due to a decline in the total return index and volatility index.
Cell MedX Corp. (CMXC) was downgraded to D+ from C- on 8/10/2016 due to a decline in the total return index and volatility index.
C
Hold
7/21/2016Upgraded
Cell MedX Corp. (CMXC) was upgraded to C- from D+ on 7/21/2016 due to an increase in the total return index, volatility index and valuation index.
Cell MedX Corp. (CMXC) was upgraded to C- from D+ on 7/21/2016 due to an increase in the total return index, volatility index and valuation index.
D
Sell
7/6/2016Downgrade
Cell MedX Corp. (CMXC) was downgraded to D+ from C- on 7/6/2016 due to a decline in the volatility index.
Cell MedX Corp. (CMXC) was downgraded to D+ from C- on 7/6/2016 due to a decline in the volatility index.
C
Hold
5/23/2016Upgraded
Cell MedX Corp. (CMXC) was upgraded to C- from D+ on 5/23/2016 due to a noticeable increase in the total return index and growth index.
Cell MedX Corp. (CMXC) was upgraded to C- from D+ on 5/23/2016 due to a noticeable increase in the total return index and growth index.
D
Sell
4/15/2016Upgraded
Cell MedX Corp. (CMXC) was upgraded to D+ from D on 4/15/2016 due to a significant increase in the efficiency index, volatility index and total return index. Net income increased 38.28% from -$479.6 to -$296, and total capital increased 12.59% from -$602.8 to -$526.9.
Cell MedX Corp. (CMXC) was upgraded to D+ from D on 4/15/2016 due to a significant increase in the efficiency index, volatility index and total return index. Net income increased 38.28% from -$479.6 to -$296, and total capital increased 12.59% from -$602.8 to -$526.9.
D
Sell
3/11/2016Downgrade
Cell MedX Corp. (CMXC) was downgraded to D from D+ on 3/11/2016 due to a major decline in the volatility index, total return index and valuation index.
Cell MedX Corp. (CMXC) was downgraded to D from D+ on 3/11/2016 due to a major decline in the volatility index, total return index and valuation index.
D
Sell
1/15/2016Upgraded
Cell MedX Corp. (CMXC) was upgraded to D+ from D on 1/15/2016 due to a substantial increase in the growth index. Total revenue increased 100% from $1.9 to $3.8.
Cell MedX Corp. (CMXC) was upgraded to D+ from D on 1/15/2016 due to a substantial increase in the growth index. Total revenue increased 100% from $1.9 to $3.8.
D
Sell
10/16/2015Downgrade
Cell MedX Corp. (CMXC) was downgraded to D from D+ on 10/16/2015 due to a significant decline in the efficiency index and growth index. Total revenue declined 94.91% from $37.3 to $1.9.
Cell MedX Corp. (CMXC) was downgraded to D from D+ on 10/16/2015 due to a significant decline in the efficiency index and growth index. Total revenue declined 94.91% from $37.3 to $1.9.
D
Sell
9/4/2015Upgraded
Cell MedX Corp. (CMXC) was upgraded to D+ from D on 9/4/2015 due to a significant increase in the efficiency index, growth index and total return index. Total revenue increased 603.77% from $5.3 to $37.3, and total capital increased 46.45% from -$322.9 to -$472.9.
Cell MedX Corp. (CMXC) was upgraded to D+ from D on 9/4/2015 due to a significant increase in the efficiency index, growth index and total return index. Total revenue increased 603.77% from $5.3 to $37.3, and total capital increased 46.45% from -$322.9 to -$472.9.
D
Sell
2/2/2015Upgraded
Cell MedX Corp. (CMXC) was upgraded to D from D- on 2/2/2015 due to an increase in the total return index.
Cell MedX Corp. (CMXC) was upgraded to D from D- on 2/2/2015 due to an increase in the total return index.
D
Sell
10/1/2014Upgraded
Sports Asylum, Inc. (SYLM) was upgraded to D- from E+ on 10/1/2014 due to a significant increase in the efficiency index and total return index. Total capital increased 36% from -$15 to -$20.4, and net income increased 22.73% from -$4.4 to -$5.4.
Sports Asylum, Inc. (SYLM) was upgraded to D- from E+ on 10/1/2014 due to a significant increase in the efficiency index and total return index. Total capital increased 36% from -$15 to -$20.4, and net income increased 22.73% from -$4.4 to -$5.4.
E
Sell
7/1/2014Upgraded
Sports Asylum, Inc. (SYLM) was upgraded to E+ from E on 7/1/2014 due to an increase in the total return index.
Sports Asylum, Inc. (SYLM) was upgraded to E+ from E on 7/1/2014 due to an increase in the total return index.
E
Sell
4/21/2014None
StimCell Energetics Inc. (STME) was downgraded to E from U on 04/21/2014.
StimCell Energetics Inc. (STME) was downgraded to E from U on 04/21/2014.
OTC PK
04/09/2025 3:57PM Eastern
Quotes delayed
